AMN Healthcare Services, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Form 8-K was filed by AMN Healthcare Services, Inc. on September 22, 2025. The report discloses a material amendment to the Company's existing Credit Agreement, originally dated February 9, 2018, involving the Company, its wholly owned subsidiary AMN Healthcare, Inc. (the Borrower), and Truist Bank as the administrative agent.
Key Financial Metrics and Debt Structure
The filing details specific changes to the Company's secured revolving credit facility:
- Facility Size: Reduced from $750.0 million to $450.0 million.
- Maturity Date: Extended from February 2028 to October 2030.
- Leverage Covenant: The Consolidated Net Leverage Ratio cap is revised to no greater than 5.25 to 1.00.
- Interest Rate Adjustments: The ten basis point credit spread adjustment regarding the Adjusted Term SOFR Adjustment is removed.
- New Pricing Tier: A new tier is added for Net Leverage Ratios >= 4.25x, setting rates at 2.00% for SOFR loans, 1.00% for Base Rate Loans, 2.00% for Letter of Credit Fees, and 0.35% for Unused Fees.
The filing text does not provide current revenue, profit, cash flow, or liquidity figures outside of the credit facility terms.
Material Changes Versus Prior Period
The primary material change is the restructuring of the credit facility terms. The reduction in facility size is offset by a significant extension of the maturity date (approximately 2.5 years) and the removal of a specific credit spread adjustment. The leverage covenant threshold has been adjusted to 5.25x.
Guidance, Outlook, and Risks
Management has confirmed that the Administrative Agent has received sufficient lender consents to proceed with the Fifth Amendment. Final documentation is expected to be executed in the fourth quarter of 2025. No specific forward-looking financial guidance or new risk factors were disclosed in this filing beyond the terms of the amended credit agreement.
Key Facts for Investor Verification
- Verify the execution of the Fifth Amendment documentation in Q4 2025.
- Confirm the impact of the reduced facility size ($450.0 million) on the Company's current liquidity needs.
- Monitor the Company's Consolidated Net Leverage Ratio to ensure compliance with the new 5.25x cap.
- Review the cost of borrowing under the new pricing tier if the Net Leverage Ratio exceeds 4.25x.